Humanigen adds Dr. John Hohneker and Dr. Kevin Xie to its Board as Independent Directors

– USA, CA –  Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm, today announced the election of Dr. John Hohneker (MD) and Dr. Kevin Xie (Ph.D.) to its Board as Independent Directors, effective October 19, 2021.

“We are excited about the depth and breadth of experience John and Kevin will add to our Board at this important time as we continue our efforts seeking regulatory authorization to commercialize lenzilumab for the treatment of hospitalized COVID-19 patients, while furthering our development of lenzilumab in CAR-T and other indications,” said Chairman and CEO, Cameron Durrant.

About Dr. John Hohneker

Dr. John Hohneker has more than 30 years of experience as an executive in the biopharmaceutical industry and he now serves as a member of the Board for five other biotechnology companies including BioTheryX, Inc. (private); Cygnal Therapeutics, Inc. (private); Aravive, Inc. (NASDAQ: ARAV); Evelo Biosciences (NASDAQ: EVLO); and Trishula Therapeutics (private). As an executive, he has advanced several programs from pre-clinical evaluation through Phase IV, including products in oncology and immunology. He played a critical role in the development and commercialization of many blockbuster products including Cosentyx, Gleevec, Zometa, Tasigna, and Afinitor. His experience includes 15 years at Novartis AG, from 2001 to 2015, where he was most recently SVP and Global Head of Development, Immunology, and Dermatology. Before Novartis, he held several positions of increasing responsibility over a nearly 11-year period beginning at Burroughs Wellcome and then with its successor Glaxo Wellcome.

Dr. Hohneker received a bachelor’s degree in chemistry from Gettysburg Collee and a medical degree from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School. He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina at Chapel Hill. In addition to his operational experience, Dr. Hohneker has direct experience leading business development and licensing deals, raising capital, and serving on corporate boards through acquisitions.

About Dr. Kevin Xie

Dr. Kevin Xie has nearly twenty years of experience evaluating and investing in companies across an array of healthcare-related industries, first for 13 years on the buy-side and then for six years in the industry where he also demonstrated the ability to add value through operational improvements. He is the CFO of Gracell Biotechnologies (Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies intended to disrupt conventional approaches to CAR-T cell therapies. As CFO at Gracell since July 2020, Dr. Xie has completed a cross-over round and IPO that raised $340 million. Before Gracell, as President of Healthcare Holdings for Fosun Group, he built and managed a team of 20 investment professionals, which invested more than $2 billion in 30+ projects in biotechnology, pharmaceutical, healthcare information technology, and healthcare services industries. Dr. Xie co-founded and served as Portfolio Manager of Locust Walk Capital. Dr. Xie had previously served as Healthcare Sector Head at Scopia Capital, and as a Managing Director at Great Point Partners. He currently serves on the Board of Directors for ViewRay (Nasdaq: VRAY).

Dr. Xie has a Bachelor of Science in Material Science and Engineering from Tianjin University, an MBA in Finance from The Wharton School of the University of Pennsylvania, and a Ph.D. in Chemistry from The City University of New York.

About Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in-class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor. Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, the investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent the consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis.

For more information: https://www.humanigen.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.